Sarepta Therapeutics Inc.‘s Duchenne muscular dystrophy therapy Vyondys 53 (golodirsen) has been approved by the US Food and Drug Administration in a surprise reversal of a rejection based on safety concerns.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?